InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,618.36
(
0.38%
)
US TECH 100
19,285.20
(
0.39%
)
Dow Jones
40,862.01
(
0.07%
)
Brent Oil
75.31
(
-1.88%
)
Bitcoin
60,147.54
(
1.93%
)
Post# of 2345122
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BobaFred

Send PM Follow Ignore
Followers 6
Posts 110
Boards Moderated 0
Alias Born 03/09/2011

BobaFred

Re: None

Tuesday, 06/18/2013 1:20:42 PM

Tuesday, June 18, 2013 1:20:42 PM

Post# of 2345122
Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal

Needham & Company's Chad Messer boosted his price target on Buy-rated Cytokinetics (NASDAQ: CYTK) from $2.50 to $3.50 Thursday, following expansion of the Amgen (NASDAQ: AMGN) deal for heart failure drug Omecamtiv in Japan.

"While a positive event in and of itself, we believe the timing of the deal reflects Amgen's confidence in the program and increases our confidence in the outcome of the ongoing Phase IIb ATOMIC-HF study, which should report out as early as this month," Messer said.
http://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Sees+150%25+Upside+in+Cytokinetics+%28CYTK%29+after+Expanded+Amgen+%28AMGN%29+Deal/8413213.html?si_client=st
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up